samedan logo
home > pmps > winter 2020 > thermoforming: the ideal product packaging solution?
Pharmaceutical Manufacturing and Packing Sourcer

Thermoforming: The Ideal Product Packaging Solution?

Pharmaceutical and medical manufacturers are under increasing pressure to achieve cost savings and improve sustainability, without compromising on all-important product safety. The latest thermoform packaging technology can provide a transformative solution to these concerns, and lead to savings at all stages of the packaging process.

The medical and pharma industries require fully reliable packaging that offers the maximum possible protection for products designed to care for and preserve the health of people. Consequently, companies in these industries require packaging solutions that meet the strictest regulations required by these sectors.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

About the author

Alastair Cook is a Product Manager at ULMA Packaging UK. He has worked for the company since its formation 18 years ago, and has been integral to the technical development of a host of ULMA packaging machinery during this time. Alastair is an expert in the packaging industry and has utilised his broad knowledge in the development of ULMA’s range of vertical and horizontal packaging machines for produce resealable packs. He specialises in the fields of thermoforming and tray sealers and has taken an active role in the development of recyclable material options for ULMA’s thermoforming range.
Print this page
Send to a friend
Privacy statement
News and Press Releases

KKR Invests in Biosynth Carbosynth to Accelerate Growth and Help Build Global Life Sciences Tools Platform

London and Staad, 1 November 2021 – KKR, a leading global investment firm, and Biosynth Carbosynth, a leading life sciences reagents and custom synthesis and manufacturing services company, announce today that KKR has agreed to acquire Biosynth Carbosynth from Armira and CEO Dr. Urs Spitz. Dr. Spitz and senior managers of the company will retain a significant ownership stake and will continue to lead the company as it embarks on its next chapter of growth. Financial details of the transaction, which is subject to customary regulatory approvals, were not disclosed.
More info >>

White Papers



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement